XML 72 R46.htm IDEA: XBRL DOCUMENT v3.6.0.2
Shareholders' Equity, Preferred and Common Shares (Details)
1 Months Ended 12 Months Ended
Feb. 17, 2017
shares
Feb. 15, 2017
shares
Aug. 29, 2016
USD ($)
$ / shares
shares
Jul. 16, 2016
shares
Jul. 05, 2016
USD ($)
shares
Jun. 16, 2016
USD ($)
$ / shares
May 13, 2016
USD ($)
shares
Feb. 28, 2017
$ / shares
shares
Oct. 31, 2015
USD ($)
Investor
$ / shares
shares
Sep. 30, 2015
USD ($)
Shareholder
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2014
Preferred Shares [Abstract]                          
Preferred shares, shares authorized (in shares)                     2,000,000 2,000,000  
Preferred shares, shares issued (in shares)                     0 0  
Preferred shares, shares outstanding (in shares)                     0 0  
Common Shares [Abstract]                          
Common shares, authorized (in shares)                     150,000,000 150,000,000  
Common shares, par value (in dollars per share) | $ / shares                     $ 0 $ 0  
Common shares, issued (in shares)                     103,396,245 94,894,140  
Common shares, outstanding (in shares)                     102,776,539 90,421,554  
Treasury stock (in shares)                     619,706 4,472,586  
Purchase price per share (in dollars per share) | $ / shares           $ 2.39              
Common shares, new shares issued (in shares)       7,322,176                  
Proceeds from sale of stock | $           $ 16,400,000              
Noncontrolling interest | $                     $ 12,580,000 $ 50,631,000  
OncoCyte Offering [Member]                          
Common Shares [Abstract]                          
Issuance of common stock and warrants (in dollars per share) | $ / shares     $ 3.25                    
OncoCyte Offering Warrants [Member]                          
Common Shares [Abstract]                          
Warrants to purchase stock (in shares)     1                    
Warrants exercised period                     5 years    
Asterias Biotherapeutics [Member]                          
Common Shares [Abstract]                          
Common shares, outstanding (in shares)                     21,700,000    
Proceeds from sale of stock | $             $ 16,200,000            
Number of shares sold (in shares)             5,147,059            
Equity method ownership percentage             57.10%       48.70%    
Percentage of ownership interest             57.10%       48.70%    
Noncontrolling interest | $                     $ 18,300,000    
Asterias Biotherapeutics [Member] | Maximum [Member]                          
Common Shares [Abstract]                          
Equity method ownership percentage                     50.00%    
Percentage of ownership interest                     50.00%    
OncoCyte Corporation [Member]                          
Common Shares [Abstract]                          
Proceeds from sale of stock | $     $ 9,800,000                    
Shares distributed to shareholders (in shares)                       4,700,000  
Shares conversion ratio                       20  
Reduction in equity method investment | $                       $ 712,000  
Equity method ownership percentage                       57.80% 76.50%
Taxable gain | $                       $ 7,400,000  
Decrease in equity method investment                       18.70%  
Issuance of common stock and warrants (in shares)     3,246,153                    
Warrants to purchase common stock (in shares)     1                    
Percentage of ownership interest                       57.80% 76.50%
Noncontrolling interest | $                     $ 4,000,000    
OncoCyte Corporation [Member] | Maximum [Member]                          
Common Shares [Abstract]                          
Equity method ownership percentage                     50.00%    
Percentage of ownership interest                     50.00%    
OncoCyte Corporation [Member] | Subsequent Event [Member]                          
Common Shares [Abstract]                          
Issuance of common stock and warrants (in shares) 625,000                        
OncoCyte Corporation [Member] | Subsequent Event [Member] | Maximum [Member]                          
Common Shares [Abstract]                          
Equity method ownership percentage 50.00%                        
Percentage of ownership interest 50.00%                        
Over-Allotment Option [Member]                          
Common Shares [Abstract]                          
Common shares, new shares issued (in shares)         1,098,326                
Proceeds from sale of stock | $         $ 2,200,000                
BioTime Common Stock [Member]                          
Common Shares [Abstract]                          
Number of shares sold (in shares)                 1,600,000 2,607,401      
Proceeds from sale of shares | $                 $ 5,100,000 $ 8,600,000      
Number of shareholders | Shareholder                   3      
Price per share (in dollars per share) | $ / shares                 $ 3.19 $ 3.29      
BioTime Common Stock [Member] | Subsequent Event [Member]                          
Common Shares [Abstract]                          
Common shares, new shares issued (in shares)   7,453,704           7,453,704          
Price per share (in dollars per share) | $ / shares               $ 2.70          
BioTime Common Stock [Member] | OncoCyte Corporation [Member]                          
Common Shares [Abstract]                          
Number of shares sold (in shares)                 246,356        
Number of investors | Investor                 1        
Price per share (in dollars per share) | $ / shares                 $ 3.13        
BioTime Common Stock [Member] | Certain investors [Member]                          
Common Shares [Abstract]                          
Number of shares sold (in shares)                 6,530,612        
Proceeds from sale of shares | $                 $ 20,400,000        
Price per share (in dollars per share) | $ / shares                 $ 3.13